{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:48:15Z","timestamp":1789534095984,"version":"build-2803163510"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Tumors frequently evade immune destruction by impairing cytotoxic CD8<jats:sup>+<\/jats:sup> T-cell responses, highlighting the need for strategies that restore T-cell functionality. Here, we identify SLAMF7 (CD319) as a key enhancer of human CD8<jats:sup>+<\/jats:sup> T-cell responses against tumors. SLAMF7 expression is induced by pro-inflammatory signals such as IL-12 and CD28 co-stimulation. Agonistic SLAMF7 signaling, in synergy with TCR activation, is able to strongly induce T-cell activation and clonal expansion, a finding consistently observed in CD8<jats:sup>+<\/jats:sup> T cells from healthy adults as well as derived from blood and tumor-draining lymph nodes of patients with head and neck squamous cell carcinoma (HNSCC). Moreover it drives a distinct differentiation programme characterized by elevated expression of key transcription factors Eomes and T-bet, leading to increased production of effector molecules such as Interferon \u03b3, Granzyme B and Perforin. In contrast to CD28 costimulation, SLAMF7 activation also promotes serial killing potential via BTLA induction. In antigen-specific human models, SLAMF7 activation boosts CD8<jats:sup>+<\/jats:sup> T-cell responses against the tumor-associated antigen NY-ESO-1, a key target in several cancers including HNSCC. Moreover, combining SLAMF7 activation with PD-1\/PD-L1 immune checkpoint blockade synergistically enhances cytokine release and cytotoxic potential, highlighting its potential to overcome immunosuppression and reinvigorate antitumor immunity.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1654374","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T05:34:40Z","timestamp":1755668080000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["SLAMF7 (CD319) enhances cytotoxic T-cell differentiation and sensitizes CD8+ T cells to immune checkpoint blockade"],"prefix":"10.3389","volume":"16","author":[{"given":"Jan-Erik","family":"Sander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette","family":"Fickenscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg-Peter","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Kroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Vosikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Durisin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Lingel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika C.","family":"Brunner-Weinzierl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2015.03.004","article-title":"Immune evasion in cancer: Mechanistic basis and therapeutic strategies","author":"Vinay","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02737","article-title":"CTLA-4 and PD-1 control of T-cell motility and migration: implications for tumor immunotherapy","volume":"9","author":"Brunner-Weinzierl","year":"2018","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2477872","DOI":"10.1080\/2162402X.2025.2477872","article-title":"Efficacy of anti-LAG3 and anti-PD-1 combination checkpoint inhibitor therapy against head and neck squamous cell carcinoma in a genetically engineered mouse model","volume":"14","author":"Lamenza","year":"2025","journal-title":"Oncoimmunology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6270","article-title":"Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma","volume":"36","author":"Robert","year":"2018","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2017.102","article-title":"CTLA-4-mediated posttranslational modifications direct cytotoxic T-lymphocyte differentiation","volume":"24","author":"Lingel","year":"2017","journal-title":"Cell Death Differ"},{"key":"B10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12974-022-02594-9","article-title":"SLAMF7 modulates B cells and adaptive immunity to regulate susceptibility to CNS autoimmunity","volume":"19","author":"O\u2019Connell","year":"2022","journal-title":"J Neuroinflamm"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.7.4672","article-title":"CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes","volume":"179","author":"Lee","year":"2007","journal-title":"J Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150224","article-title":"SLAMF7 regulates the inflammatory response in macrophages during polymicrobial sepsis","volume":"133","author":"Wu","year":"2023","journal-title":"J Clin Invest"},{"key":"B13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/eji.202149406","article-title":"SLAMF7 selectively favors degranulation to promote cytotoxicity in human NK cells","volume":"52","author":"Gutierrez-Guerrero","year":"2022","journal-title":"Eur J Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/ni.1693","article-title":"Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function","volume":"10","author":"Cruz-Munoz","year":"2009","journal-title":"Nat Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-024-01399-y","article-title":"SLAMF7 (CD319) on activated CD8+ T cells transduces environmental cues to initiate cytotoxic effector cell responses","volume":"32","author":"Lingel","year":"2024","journal-title":"Cell Death Differ"},{"key":"B16","doi-asserted-by":"publisher","first-page":"7996","DOI":"10.4049\/jimmunol.175.12.7996","article-title":"The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3K and phospholipase Cgamma signaling pathways in human NK cells","volume":"175","author":"Tassi","year":"2005","journal-title":"J Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02551","article-title":"Mechanisms of NK cell activation and clinical activity of the therapeutic SLAMF7 antibody, elotuzumab in multiple myeloma","volume":"9","author":"Campbell","year":"2018","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1339853","article-title":"The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms","volume":"6","author":"Pazina","year":"2017","journal-title":"Oncoimmunology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2018.014","article-title":"Elotuzumab for the treatment of relapsed or refractory multiple myeloma, with special reference to its modes of action and SLAMF7 signaling","volume":"10","author":"Taniwaki","year":"2018","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nature22076","article-title":"SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin","volume":"544","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.12.1330","article-title":"Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease","volume":"138","author":"Mattoo","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"6357","DOI":"10.1038\/s41467-020-19002-6","article-title":"SLAMF7 and IL-6R define distinct cytotoxic versus helper memory CD8+ T cells","volume":"11","author":"Loyal","year":"2020","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1\u201313","DOI":"10.1126\/sciadv.abe3348","article-title":"Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer","volume":"7","author":"Cachot","year":"2021","journal-title":"Sci Adv"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/art.40038","article-title":"Signaling lymphocytic activation molecule family member 7 engagement restores defective effector CD8+ T cell function in systemic lupus erythematosus","volume":"69","author":"Comte","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01172-x","article-title":"Selective elimination of immunosuppressive T cells in patients with multiple myeloma","volume":"35","author":"Awwad","year":"2021","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4049\/jimmunol.2000300","article-title":"SLAMF7 signaling reprograms T cells toward exhaustion in the tumor microenvironment","volume":"206","author":"O\u2019Connell","year":"2021","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2010.02.013","article-title":"Inflammatory cytokines as a third signal for T cell activation","volume":"22","author":"Curtsinger","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/ijms11030789","article-title":"Interleukin 12 a key immunoregulatory cytokine in infection applications","volume":"11","author":"Hamza","year":"2010","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.suppl_1.i109","article-title":"Advances in interleukin 2 receptor targeted treatment","author":"Morris","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830210214","article-title":"T cell activation in the absence of interleukin 2 (IL 2) results in the induction of high-affinity IL 2 receptor unable to transmit a proliferative signal","volume":"21","author":"Proust","year":"1991","journal-title":"Eur J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00630","article-title":"PD-1 primarily targets TCR signal in the inhibition of functional T cell activation","volume":"10","author":"Mizuno","year":"2019","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-8885-3_7","article-title":"CD107a degranulation assay to evaluate immune cell antitumor activity","volume":"1884","author":"Lorenzo-Herrero","year":"2019","journal-title":"Methods Mol Biol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0022-1759(03)00265-5","article-title":"Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation","volume":"281","author":"Betts","year":"2003","journal-title":"J Immunol Methods"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2004.12.006","article-title":"CD69 is an immunoregulatory molecule induced following activation","volume":"26","author":"Sancho","year":"2005","journal-title":"Trends Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646837","article-title":"CD69: from activation marker to metabolic gatekeeper","volume":"47","author":"Cibri\u00e1n","year":"2017","journal-title":"Eur J Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02618","article-title":"CD137 (4-1BB) signalosome: complexity is a matter of TRAFs","volume":"9","author":"Zapata","year":"2018","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056168","article-title":"Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities","volume":"110","author":"Wolfl","year":"2007","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.immuni.2009.11.012","article-title":"Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells","volume":"32","author":"Pipkin","year":"2010","journal-title":"Immunity"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/ni1268","article-title":"Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin","volume":"6","author":"Intlekofer","year":"2005","journal-title":"Nat Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1126\/science.1090148","article-title":"Control of effector CD8 + T cell function by the transcription factor eomesodermin","volume":"302","author":"Pearce","year":"2003","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.4.2124","article-title":"Granzyme B and the downstream granzymes C and\/or F are important for cytotoxic lymphocyte functions","volume":"174","author":"Revell","year":"2005","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90376-X","article-title":"Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells","volume":"76","author":"Heusel","year":"1994","journal-title":"Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.20.100201.131730","article-title":"Lymphocyte-mediated cytotoxicity","volume":"20","author":"Russell","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4402289","article-title":"Granzyme B-induced cell death exerted by ex vivo CTL: discriminating requirements for cell death and some of its signs","volume":"15","author":"Pardo","year":"2008","journal-title":"Cell Death Differ"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.67","article-title":"Interferon-\u03b3 derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity","volume":"8","author":"Bhat","year":"2017","journal-title":"Cell Death Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/369031a0","article-title":"Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice","volume":"369","author":"K\u00e4gi","year":"1994","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13668","article-title":"Faster cytotoxicity with age: Increased perforin and granzyme levels in cytotoxic CD8+ T cells boost cancer cell elimination","volume":"21","author":"Z\u00f6phel","year":"2022","journal-title":"Aging Cell"},{"key":"B48","doi-asserted-by":"publisher","first-page":"30816","DOI":"10.1038\/srep30816","article-title":"Ceramide mediates FasL-induced caspase 8 activation in colon carcinoma cells to enhance FasL-induced cytotoxicity by tumor-specific cytotoxic T lymphocytes","volume":"6","author":"Coe","year":"2016","journal-title":"Sci Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.5.2402","article-title":"The Fas\/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases","volume":"171","author":"Caldwell","year":"2003","journal-title":"J Immunol"},{"key":"B50","article-title":"Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients","volume":"60","author":"Valmori","year":"2000","journal-title":"Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of cancer: current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 costimulation: from mechanism to therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1217","article-title":"Multifaceted role of BTLA in the control of CD8+ T-cell fate after antigen encounter","volume":"23","author":"Ritthipichai","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2230-0","article-title":"IL-10 inducible CD8+ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells","volume":"67","author":"Plaumann","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.7.3188","article-title":"Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells","volume":"160","author":"Groux","year":"1998","journal-title":"J Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","article-title":"The two faces of IL-6 in the tumor microenvironment","volume":"26","author":"Fisher","year":"2014","journal-title":"Semin Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.03.010","article-title":"Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells","volume":"128","author":"Kobayashi","year":"2005","journal-title":"Gastroenterology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2636938100","article-title":"Antigen-driven effector CD8 T cell function regulated by T-bet","volume":"100","author":"Sullivan","year":"2003","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1126\/science.1065543","article-title":"Distinct effects of T-bet in T H 1 lineage commitment and IFN-\u03b3 Production in CD4 and CD8 T cells","volume":"295","author":"Szabo","year":"2002","journal-title":"Science"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2050","article-title":"Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells","volume":"12","author":"Thiery","year":"2011","journal-title":"Nat Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nri1083","article-title":"The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal","volume":"3","author":"Lieberman","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2007.04.011","article-title":"Delivering the kiss of death: progress on understanding how perforin works","volume":"19","author":"Pipkin","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3442","article-title":"Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas","volume":"20","author":"Afshar-Sterle","year":"2014","journal-title":"Nat Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"281613","DOI":"10.1155\/2015\/281613","article-title":"Fas\/FasL pathway participates in regulation of antiviral and inflammatory response during mousepox infection of lungs","volume":"2015","author":"Bie\u0144","year":"2015","journal-title":"Mediators Inflammation"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092184","article-title":"Fine specificity and molecular competition in SLAM family receptor signalling","volume":"9","author":"Wilson","year":"2014","journal-title":"PloS One"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.958616","article-title":"T cell-specific constitutive active SHP2 enhances T cell memory formation and reduces T cell activation","volume":"13","author":"Cammann","year":"2022","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200636240","article-title":"The tyrosine phosphatase SHP-2 regulates differentiation and apoptosis of individual primary T lymphocytes","volume":"37","author":"Hoff","year":"2007","journal-title":"Eur J Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adh1306","article-title":"BCL6 promotes a stem-like CD8+ T cell program in cancer via antagonizing BLIMP1","volume":"8","author":"Sun","year":"2023","journal-title":"Sci Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.22.12.4062-4072.2002","article-title":"Receptor-specific regulation of phosphatidylinositol 3\u2019-kinase activation by the protein tyrosine phosphatase Shp2","volume":"22","author":"Zhang","year":"2002","journal-title":"Mol Cell Biol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1042\/BCJ20200661","article-title":"Extracellular signal-regulated kinase (ERK) pathway control of CD8+ T cell differentiation","volume":"478","author":"Damasio","year":"2021","journal-title":"Biochem J"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.715234","article-title":"CD8+ T cell exhaustion in cancer","volume":"12","author":"Dolina","year":"2021","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"226.11","DOI":"10.4049\/jimmunol.210.Supp.226.11","article-title":"PD-1 signaling serves a dual role in suppressing T cell activation but also in protecting from activation-induced cell death","volume":"210","author":"Vick","year":"2023","journal-title":"J Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00281-018-0703-z","article-title":"Principles of adoptive T cell therapy in cancer","volume":"41","author":"Met","year":"2019","journal-title":"Semin Immunopathol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1654374\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T05:34:42Z","timestamp":1755668082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1654374\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":78,"alternative-id":["10.3389\/fimmu.2025.1654374"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1654374","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"article-number":"1654374"}}